Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy

Cancer

Volumn 94, Issue 2, 2002, Pages 421-427

  Leung, Thomas W T ^a,b   Tang, Amanda M Y ^a,b   Zee, Benny ^a   Yu, Simon C H ^a   Lai, Paul B S ^b   Lau, Wan Yee ^b   Johnson, Philip J ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chemotherapy; Hepatocellular carcinoma; Multivariate analysis; Prognosticators

Indexed keywords

BILIRUBIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; RECOMBINANT ALPHA2B INTERFERON;

ADOLESCENT; ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME; VASCULAR DISEASE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIRUBIN; CARCINOMA, HEPATOCELLULAR; CHILD; CISPLATIN; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INTERFERON ALFA-2B; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; REMISSION INDUCTION; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037080414     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10236     Document Type: Article

References (23)

1. Estimates of the worldwide frequency of twelve major cancers
2. Increase in primary liver cancer in the UK, 1979-94
3. Rising incidence of hepatocellular carcinoma in the United States
4. Primary liver cancers in Japan
5. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients
6. Natural history of untreated primary hepatocellular carcinoma: A retrospective study of 157 patients
7. Prognostic factors of hepatocellular carcinoma in the west: A multivariate analysis in 206 patients
8. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma
9. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma
10. Chemotherapy for hepatocellular carcinoma
11. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma
12. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: Study of 850 patients
13. Non-surgical management of hepatocellular carcinoma
14. Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials
15. Overview of medical treatments in unresectable hepatocellular carcinoma - An impossible meta-analysis?
16. Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: A communication
17. Significance of serum bilirubin level in response of hepatocellular carcinoma to doxorubicin
18. Chemotherapy in hepatocellular carcinoma
19. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: A multivariate analysis of prognostic factors
20. Hepatocellular carcinoma in the United States: Prognostic features, treatment outcome and survival
21. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients: The Cancer of the Liver Italian Program (CLIP) Investigators